Clinical Trial Update: Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) [Phase 4]

View source ↗

Summary

Open-label Phase IV study evaluating secukinumab for nail psoriasis and enthesitis in psoriasis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: University of Pennsylvania | Conditions: Psoriasis | Phase 4 | Status: COMPLETED